ABT vs BLLN: fair value comparison
Abbott Laboratories and BillionToOne, Inc. · Updated 2026-10-19
BLLN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, ABT currently ranks higher by quality score.
| ABT | BLLN | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $99.60 | $98.12 |
| 12-month range | $82.56–$130.59 | $64.03–$149.97 |
| Rank by discount to fair value | #26 of 108 Healthcare | — |
| Rank by quality score | #73 of 301 Healthcare | #75 of 301 Healthcare |
| Quality grade | B | B |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: ABT fair value analysis · BLLN fair value analysis